StockData
Medline Inc. logo

Medline Inc. (MDLN) stock

MDLNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 2/3060% above fair value
$39.16+1.48 (+3.93%)

Close on Nov 18, 2026Market cap $51.48BP/E –Yield –

Earnings

Medline's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 24, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$7.90B
Adjusted Diluted EPS, Q3 FY2026
$0.44
Latest guidance
Issued
Nov 4, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Medline's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 24, 2027Expected–––––
Q3 FY2026ended Sep 26, 2026Nov 4, 2026before the open$7.90B–$0.22$0.44Release
Q2 FY2026ended Jun 27, 2026Aug 5, 2026before the open$7.70B–$0.07$0.50Release
Q1 FY2026ended Mar 28, 2026May 6, 2026before the open$7.40B–$0.16$0.33Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026before the open$7.80B–-$0.01–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Medline's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Organic Salesnon-GAAPFY2026+10% – +10.5%–NewNov 4, 2026
Organic Salesnon-GAAPFY2026+9% – +10%+8.5% – +9.5%RaisedAug 5, 2026
Adjusted EBITDAnon-GAAPFY2026$3.30B – $3.40B–NewNov 4, 2026
Adjusted EBITDAnon-GAAPFY2026$3.30B – $3.40B$3.50B – $3.60BLoweredAug 5, 2026

Guidance history

Every forecast Medline put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026Adjusted EBITDAFY2026$3.30B – $3.40BNew
Nov 4, 2026Organic SalesFY2026+10% – +10.5%New
Aug 5, 2026Adjusted EBITDAFY2026$3.30B – $3.40BLowered
Aug 5, 2026Organic SalesFY2026+9% – +10%Raised
May 6, 2026Adjusted EBITDAFY2026$3.50B – $3.60BReaffirmed
May 6, 2026Organic Sales growthFY2026+8.5% – +9.5%Raised
Feb 25, 2026Adjusted EBITDAFY2026$3.50B – $3.60BNew
Feb 25, 2026Organic SalesFY2026+8% – +9%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Medline filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?